The development of new medicines is often hindered by a lack of data, despite data being essential to understanding the complex behavior of biological systems. To address this, scientists are increasingly applying large datasets to train and implement AI across many aspects of drug development.
However, current methods for generating data typically rely on cells grown in bulk populations, a process that is slow, costly, provides an insufficient amount of data, and obscures the biological heterogeneity that exists between individual cells.
Samplix has therefore developed Xdrop® Plus, a single-cell platform that enables functional analysis at true single-cell resolution. Instead of building a complicated and expensive system, Samplix has created a solution that prepares single cells for analysis on standard laboratory instruments, making the technology accessible to most laboratories.
The Xdrop Plus platform integrates instruments, microfluidic cartridges, reagents, other consumables, and software tools to support both experimental setup and data analysis.
The platform has already been proven, in peer-reviewed publications, to enhance the analysis of immune cells for immunotherapies such as tumour-infiltrating lymphocyte (TIL) treatments and CAR-T therapies.
It has also demonstrated significant value in the discovery and development of new antibodies, including therapeutics. With Xdrop Plus, millions of antibody-producing cells can be screened, allowing those with the desired functionality to be identified and further characterised.
Looking ahead, future applications of the technology include enzyme engineering to replace chemical processes with sustainable solutions, rapid vaccine development in response to pandemics, and high-throughput screening of molecular libraries for medical purposes.
